Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024

Benzinga · Aug 21 23:41

- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year end 2024

- Mini oral presentation to highlight initial Phase 1 data from potential first-in-class CDK2 inhibitor program in patients with CCNE1 ovarian and other advanced cancers

- Incyte to host an in-person analyst and investor event to review key data at ESMO, including new results from a later CDK2 data cut-off, on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST)

Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024

Risk Disclaimer